Closed · RFA-AA-23-006 · CFDA 93.213;93.273;93.279;93.866 · Discretionary
HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $250K
- Award range
- Closed
- Status
- December 14, 2023
- Close date
- -
- Expected awards
The verdict
HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $250,000. Future funding cycles may be published under the same CFDA number.
- up to $250K
- award range
- Closed
- application status
- 93.213;93.273;93.279;93.866
- CFDA program
Opportunity snapshot. This Grants.gov announcement - HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional) - is cataloged under number RFA-AA-23-006 and tied to CFDA assistance listing 93.213;93.273;93.279;93.866, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on September 11, 2023 and last updated on September 12, 2023. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Up to $250,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on December 14, 2023. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $250,000
Close Date
December 14, 2023
Posted
September 11, 2023
Instrument
Grant
Description
This notice of funding opportunity (NOFO) seeks to support studies that will inform safe and effective medication-assisted, psychosocial, and complementary interventions for people with co-occurring Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). Alcohol increases lethal opioid overdose risk. As a result, treatment providers may under-prescribe or be reluctant to provide opioid agonist therapies (OATs) such as methadone and buprenorphine to people with OUD who also have AUD or misuse alcohol. There is also scant research on non-pharmacological therapies for people with OUD-AUD. Reciprocal relationships between opioid use and alcohol use has been observed for OUD-AUD patients such that reduced opioid intake may result in increased drinking which heightens opioid relapse and overdose risk and suggests an urgent need for targeted therapies in this population. Research projects dedicated to OUD treatment and prevention, while not excluding subjects who drink, seldom explicitly recruit subjects with AUD. The purpose of this NOFO is to support clinical research project development, including piloting study design and research protocols, subject recruitment, and initiating data collection and analysis pertinent to studying treatment practices for people with OUD-AUD.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH Grants Information grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |